Chapter 12 Liposome-Mediated Therapy of Neuroblastoma

Daniela Di Paolo, Monica Loi, Fabio Pastorino, Chiara Brignole, Danilo Marimpietri, Pamela Becherini, Irene Caffa, Alessia Zorzoli, Renato Longhi, Cristina Gagliani, Carlo Tacchetti, Angelo Corti, Theresa M. Allen, Mirco Ponzoni, Gabriella Pagnan

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Neuroblastoma (NB) is the most common extracranial solid tumor in childhood and the most frequently diagnosed neoplasm during infancy. Despite of aggressive treatment strategies, the 5-year survival rate for metastatic disease is still less than 60% and, consequently, novel therapeutic approaches are needed. For increasing the therapeutic index of anticancer drugs, while reducing side effects, one of the most promising strategies in modern chemotherapy is based on the development of innovative drug delivery systems, such as liposomes. "Anticancer drug"-loaded liposomes have demonstrated enhanced ability to target to the affected area, as well as increased antitumor efficacy compared to conventional drugs. Liposomes tend to extravasate preferentially and to accumulate into tumor interstitial fluids, due to the defective structure of the new angiogenic vessels within the tumor masses. This inherent tumor selectivity can be increased further by coupling tumor-specific antibodies or other targeting moieties to the surface of the lipid envelope. Here, we describe the methodology used in these studies, as well as the antitumor results obtained by the use of several "anticancer drugs," encapsulated into antibody- and peptide-targeted liposomal formulations, against NB.

Original languageEnglish
Pages (from-to)225-249
Number of pages25
JournalMethods in Enzymology
Volume465
Issue numberC
DOIs
Publication statusPublished - 2009

Fingerprint

Neuroblastoma
Liposomes
Tumors
Neoplasms
Pharmaceutical Preparations
Neoplasm Antibodies
Therapeutics
Chemotherapy
Antibodies
Extracellular Fluid
Drug Delivery Systems
Lipids
Drug Therapy
Peptides
Fluids

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology

Cite this

Chapter 12 Liposome-Mediated Therapy of Neuroblastoma. / Di Paolo, Daniela; Loi, Monica; Pastorino, Fabio; Brignole, Chiara; Marimpietri, Danilo; Becherini, Pamela; Caffa, Irene; Zorzoli, Alessia; Longhi, Renato; Gagliani, Cristina; Tacchetti, Carlo; Corti, Angelo; Allen, Theresa M.; Ponzoni, Mirco; Pagnan, Gabriella.

In: Methods in Enzymology, Vol. 465, No. C, 2009, p. 225-249.

Research output: Contribution to journalArticle

Di Paolo, Daniela ; Loi, Monica ; Pastorino, Fabio ; Brignole, Chiara ; Marimpietri, Danilo ; Becherini, Pamela ; Caffa, Irene ; Zorzoli, Alessia ; Longhi, Renato ; Gagliani, Cristina ; Tacchetti, Carlo ; Corti, Angelo ; Allen, Theresa M. ; Ponzoni, Mirco ; Pagnan, Gabriella. / Chapter 12 Liposome-Mediated Therapy of Neuroblastoma. In: Methods in Enzymology. 2009 ; Vol. 465, No. C. pp. 225-249.
@article{8bdab244b82e491eb1465956cb85fb2c,
title = "Chapter 12 Liposome-Mediated Therapy of Neuroblastoma",
abstract = "Neuroblastoma (NB) is the most common extracranial solid tumor in childhood and the most frequently diagnosed neoplasm during infancy. Despite of aggressive treatment strategies, the 5-year survival rate for metastatic disease is still less than 60{\%} and, consequently, novel therapeutic approaches are needed. For increasing the therapeutic index of anticancer drugs, while reducing side effects, one of the most promising strategies in modern chemotherapy is based on the development of innovative drug delivery systems, such as liposomes. {"}Anticancer drug{"}-loaded liposomes have demonstrated enhanced ability to target to the affected area, as well as increased antitumor efficacy compared to conventional drugs. Liposomes tend to extravasate preferentially and to accumulate into tumor interstitial fluids, due to the defective structure of the new angiogenic vessels within the tumor masses. This inherent tumor selectivity can be increased further by coupling tumor-specific antibodies or other targeting moieties to the surface of the lipid envelope. Here, we describe the methodology used in these studies, as well as the antitumor results obtained by the use of several {"}anticancer drugs,{"} encapsulated into antibody- and peptide-targeted liposomal formulations, against NB.",
author = "{Di Paolo}, Daniela and Monica Loi and Fabio Pastorino and Chiara Brignole and Danilo Marimpietri and Pamela Becherini and Irene Caffa and Alessia Zorzoli and Renato Longhi and Cristina Gagliani and Carlo Tacchetti and Angelo Corti and Allen, {Theresa M.} and Mirco Ponzoni and Gabriella Pagnan",
year = "2009",
doi = "10.1016/S0076-6879(09)65012-6",
language = "English",
volume = "465",
pages = "225--249",
journal = "ImmunoMethods",
issn = "1046-2023",
publisher = "Academic Press Inc.",
number = "C",

}

TY - JOUR

T1 - Chapter 12 Liposome-Mediated Therapy of Neuroblastoma

AU - Di Paolo, Daniela

AU - Loi, Monica

AU - Pastorino, Fabio

AU - Brignole, Chiara

AU - Marimpietri, Danilo

AU - Becherini, Pamela

AU - Caffa, Irene

AU - Zorzoli, Alessia

AU - Longhi, Renato

AU - Gagliani, Cristina

AU - Tacchetti, Carlo

AU - Corti, Angelo

AU - Allen, Theresa M.

AU - Ponzoni, Mirco

AU - Pagnan, Gabriella

PY - 2009

Y1 - 2009

N2 - Neuroblastoma (NB) is the most common extracranial solid tumor in childhood and the most frequently diagnosed neoplasm during infancy. Despite of aggressive treatment strategies, the 5-year survival rate for metastatic disease is still less than 60% and, consequently, novel therapeutic approaches are needed. For increasing the therapeutic index of anticancer drugs, while reducing side effects, one of the most promising strategies in modern chemotherapy is based on the development of innovative drug delivery systems, such as liposomes. "Anticancer drug"-loaded liposomes have demonstrated enhanced ability to target to the affected area, as well as increased antitumor efficacy compared to conventional drugs. Liposomes tend to extravasate preferentially and to accumulate into tumor interstitial fluids, due to the defective structure of the new angiogenic vessels within the tumor masses. This inherent tumor selectivity can be increased further by coupling tumor-specific antibodies or other targeting moieties to the surface of the lipid envelope. Here, we describe the methodology used in these studies, as well as the antitumor results obtained by the use of several "anticancer drugs," encapsulated into antibody- and peptide-targeted liposomal formulations, against NB.

AB - Neuroblastoma (NB) is the most common extracranial solid tumor in childhood and the most frequently diagnosed neoplasm during infancy. Despite of aggressive treatment strategies, the 5-year survival rate for metastatic disease is still less than 60% and, consequently, novel therapeutic approaches are needed. For increasing the therapeutic index of anticancer drugs, while reducing side effects, one of the most promising strategies in modern chemotherapy is based on the development of innovative drug delivery systems, such as liposomes. "Anticancer drug"-loaded liposomes have demonstrated enhanced ability to target to the affected area, as well as increased antitumor efficacy compared to conventional drugs. Liposomes tend to extravasate preferentially and to accumulate into tumor interstitial fluids, due to the defective structure of the new angiogenic vessels within the tumor masses. This inherent tumor selectivity can be increased further by coupling tumor-specific antibodies or other targeting moieties to the surface of the lipid envelope. Here, we describe the methodology used in these studies, as well as the antitumor results obtained by the use of several "anticancer drugs," encapsulated into antibody- and peptide-targeted liposomal formulations, against NB.

UR - http://www.scopus.com/inward/record.url?scp=71849103407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71849103407&partnerID=8YFLogxK

U2 - 10.1016/S0076-6879(09)65012-6

DO - 10.1016/S0076-6879(09)65012-6

M3 - Article

VL - 465

SP - 225

EP - 249

JO - ImmunoMethods

JF - ImmunoMethods

SN - 1046-2023

IS - C

ER -